AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17272618 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (12 mg)
Number of subjects: 249
Study 17272618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 16240958 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 0
Study 16240958 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond Solo Plus Total‐Etch
Number of subjects: 0
Study 16240958 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond Solo Plus Self‐Etch
Number of subjects: 0
Study 16240958 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 11890845 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 10
Study 11890845 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 10
Study 9866000 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 micrograms every 3 h for a maximum of five doses in 24 h)
Number of subjects: 140
Study 9866000 — intervention group
Group type: COMPARATOR
Intervention: Vaginal gemeprost (1 mg every 3 h for a maximum of five doses in 24 h)
Number of subjects: 140
Study 9097753 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (oral administration, acute dose)
Number of subjects: 31
Study 9097753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 2771438 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural bupivacaine infusion
Number of subjects: 0
Study 2771438 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular narcotic analgesia
Number of subjects: 0
Study 340134 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (single oral dose of 50 mg/kg)
Number of subjects: 100
Study 340134 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (single oral dose of 50 mg/kg)
Number of subjects: 100
Study 340134 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 100
Study 340134 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 100
Study 31144240 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (10 Âµmol/L) in hyperglycemia (30 mmol/L)
Number of subjects: 3
Study 31144240 — intervention group
Group type: COMPARATOR
Intervention: Hyperglycemia (30 mmol/L)
Number of subjects: 3
Study 31144240 — intervention group
Group type: COMPARATOR
Intervention: Normoglycemia (5.5 mmol/L)
Number of subjects: 3
Study 27856240 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-step procedure
Number of subjects: 1878
Study 27856240 — intervention group
Group type: COMPARATOR
Intervention: 2-step procedure
Number of subjects: 1878
Study 26554457 — intervention group
Group type: EXPERIMENTAL
Intervention: Power training (high-velocity, high-intensity progressive resistance training) at 80%1RM, 3 days per week for 12 months
Number of subjects: 103
Study 26554457 — intervention group
Group type: COMPARATOR
Intervention: Sham exercise control group (non-progressive, low-intensity training)
Number of subjects: 103
Study 23646467 — intervention group
Group type: EXPERIMENTAL
Intervention: Yang deficiency group
Number of subjects: 145
Study 23646467 — intervention group
Group type: COMPARATOR
Intervention: Yin deficiency group
Number of subjects: 145
Study 23646467 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 145
Study 21212932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest tertile of serum potassium (2.8-3.9 mmol/l)
Number of subjects: 4409
Study 21212932 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum potassium level
Number of subjects: 4409
Study 19302913 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic formulation of topiramate 100 mg
Number of subjects: 28
Study 19302913 — intervention group
Group type: COMPARATOR
Intervention: Branded formulation of topiramate 100 mg
Number of subjects: 28
Study 17761627 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-hour training session in communication skills and tobacco cessation counseling
Number of subjects: 104
Study 17761627 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 17761627 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 104
Study 15187074 — intervention group
Group type: EXPERIMENTAL
Intervention: SPPARO (System Providing Patients Access to Records Online)
Number of subjects: 394
Study 11584936 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlogenzym (2-3 tablets, bid)
Number of subjects: 50
Study 11584936 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium 50 mg bid
Number of subjects: 50
Study 9689205 — intervention group
Group type: EXPERIMENTAL
Intervention: Alora (0.05 mg/day applied for 3‐4 days)
Number of subjects: 27
Study 9689205 — intervention group
Group type: COMPARATOR
Intervention: Climara (0.05 mg/day applied for 7 days)
Number of subjects: 27
Study 8270987 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (IFN) 50 x 10(6) IU
Number of subjects: 287
Study 8270987 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin (MIT‐C) 40 mg
Number of subjects: 287
Study 2504944 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 457
Study 2504944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study 359492 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg oxyfedrine i.v. in 10 patients
Number of subjects: 15
Study 359492 — intervention group
Group type: COMPARATOR
Intervention: Placebo in 5 patients
Number of subjects: 15
Study 31690179 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Number of subjects: 51769
Study 31690179 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy after positive flexible sigmoidoscopy
Number of subjects: 51769
Study 31690179 — intervention group
Group type: COMPARATOR
Intervention: Faecal occult blood test (control)
Number of subjects: 51769
Study 28711472 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (NMDAR antagonist)
Number of subjects: 30
Study 28711472 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (nAChR agonist)
Number of subjects: 30
Study 28711472 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine + Nicotine
Number of subjects: 30
Study 28711472 — intervention group
Group type: COMPARATOR
Intervention: Ketamine (compared to schizophrenia patients)
Number of subjects: 30
Study 26819186 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive treatment (VAAPS)
Number of subjects: 145
Study 26819186 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Bascom cleft lift procedure)
Number of subjects: 145
Study 24836780 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea gargling (3 times a day with bottled green tea)
Number of subjects: 757
Study 24836780 — intervention group
Group type: COMPARATOR
Intervention: Water gargling (3 times a day with tap water)
Number of subjects: 757
Study 22934446 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic pioglitazone (15 mg once daily)
Number of subjects: 60
Study 22934446 — intervention group
Group type: COMPARATOR
Intervention: Original pioglitazone (15 mg once daily)
Number of subjects: 60
Study 20509069 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality hypnosis (VRH)
Number of subjects: 21
Study 20509069 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive VR without hypnosis
Number of subjects: 21
Study 20509069 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 21
Study 18824708 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg sorafenib twice per day
Number of subjects: 56
Study 18824708 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg sorafenib twice per day
Number of subjects: 56
Study 18824708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 15962376 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐wk regimen consisting of ranitidine bismuth citrate 400 mg b.i.d. with clarithromycin 500 mg b.i.d.
Number of subjects: 120
Study 15962376 — intervention group
Group type: COMPARATOR
Intervention: 2‐wk regimen consisting of ranitidine bismuth citrate 400 mg b.i.d. with clarithromycin 500 mg b.i.d.
Number of subjects: 120
Study 11823757 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg for 7 days, followed by 400 mg for 21 days)
Number of subjects: 41
Study 11823757 — intervention group
Group type: COMPARATOR
Intervention: Placebo (28 days)
Number of subjects: 41
Study 10383006 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling on protein restriction
Number of subjects: 121
Study 10383006 — intervention group
Group type: COMPARATOR
Intervention: Usual dietary advice
Number of subjects: 121
Study 8645625 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 40 mg o.d. (group 1)
Number of subjects: 13
Study 8645625 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 100 mg o.d. (group 2)
Number of subjects: 13
Study 1757907 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mannitol
Number of subjects: 20
Study 1757907 — intervention group
Group type: COMPARATOR
Intervention: Oral sodium taurocholate
Number of subjects: 20
Study 6139318 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol, 5 mg the evening before and on the morning, an hour prior to surgery
Number of subjects: 36
Study 6139318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 30975187 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized morphine titration (NMT) for 5-25 min with IV placebo (physiologic serum)
Number of subjects: 850
Study 30975187 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine titration (IVMT) plus nebulized placebo (physiologic serum)
Number of subjects: 850
Study 29645086 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus pazopanib (erlotinib 150 mg daily, pazopanib 600 mg daily)
Number of subjects: 192
Study 29645086 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib plus placebo (erlotinib 150 mg daily)
Number of subjects: 192
Study 29645086 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus pazopanib
Number of subjects: 192
Study 26760383 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki therapy
Number of subjects: 43
Study 26760383 — intervention group
Group type: COMPARATOR
Intervention: Non-Reiki (control)
Number of subjects: 43
Study 24337078 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg)
Number of subjects: 44
Study 24337078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 22503396 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy
Number of subjects: 753
Study 22503396 — intervention group
Group type: COMPARATOR
Intervention: Total abdominal hysterectomy
Number of subjects: 753
Study 20687361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis
Number of subjects: 377
Study 20687361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis
Number of subjects: 377
Study 20687361 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion CT (pCT) diagnostics
Number of subjects: 377
Study 18551086 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/day for 15 days
Number of subjects: 83
Study 16079686 — intervention group
Group type: EXPERIMENTAL
Intervention: Showering the surgical site with soap and water and rinsing with normal saline
Number of subjects: 1810
Study 16079686 — intervention group
Group type: COMPARATOR
Intervention: Traditional method of preoperative shower and scrub with chlorhexidine or Betadine
Number of subjects: 1810
Study 12401597 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mL/kg of 0.25% bupivacaine
Number of subjects: 50
Study 12401597 — intervention group
Group type: COMPARATOR
Intervention: 1.0 mL/kg of 0.2% bupivacaine
Number of subjects: 50
Study 10444538 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat preload (1 MJ)
Number of subjects: 10
Study 10444538 — intervention group
Group type: COMPARATOR
Intervention: Simple carbohydrate (CHO) preload (1 MJ)
Number of subjects: 10
Study 8632199 — intervention group
Group type: EXPERIMENTAL
Intervention: Carkhuff model of communication skills training (20 hours)
Number of subjects: 24
Study 8632199 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 24
Study 2284217 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam (4 mg dose, administered as an aqueous solution, orally and intravenously)
Number of subjects: 0
Study 7349619 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 9
Study 31094635 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealants with adhesive layer (light-cured separately)
Number of subjects: 72
Study 31094635 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealants with uncured adhesive layer
Number of subjects: 72
Study 31094635 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealants without adhesive layer
Number of subjects: 72
Study 31094635 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraseal XT sealants with adhesive layer
Number of subjects: 72
Study 31094635 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealants with adhesive layer (light cured together with sealant)
Number of subjects: 72
Study 28068794 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver strain (CSI)
Number of subjects: 195
Study 28068794 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety (HADS)
Number of subjects: 195
Study 28068794 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression (HADS)
Number of subjects: 195
Study 28068794 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (SF‐36, EuroQol‐VAS)
Number of subjects: 195
Study 26215551 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Number of subjects: 116
Study 26215551 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid Injection (CSI)
Number of subjects: 116
Study 23486303 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency transcutaneous electrical nerve stimulation (TENS) applied on bilateral tender points of trapezium and supraspinatus
Number of subjects: 28
Study 23486303 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 28
Study 21941089 — intervention group
Group type: EXPERIMENTAL
Intervention: Heberbiovac-HB
Number of subjects: 400
Study 21941089 — intervention group
Group type: EXPERIMENTAL
Intervention: Euvax-B
Number of subjects: 400
Study 21941089 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepavax-Gene
Number of subjects: 400
Study 21941089 — intervention group
Group type: EXPERIMENTAL
Intervention: Engerix-B
Number of subjects: 400
Study 19391153 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist flexibility in cognitive-behavioral therapy
Number of subjects: 63
Study 20463410 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin (2.5‐100 mg/d)
Number of subjects: 4607
Study 20463410 — intervention group
Group type: COMPARATOR
Intervention: comparator (placebo, metformin, uptitrated glyburide)
Number of subjects: 4607
Study 16143229 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 37.5 mg/day
Number of subjects: 40
Study 12396765 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counselling or therapy
Number of subjects: 27
Study 12396765 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy
Number of subjects: 27
Study 12396765 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 27
Study 10199763 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa plus spironolactone (100 mg, orally, once daily)
Number of subjects: 41
Study 10199763 — intervention group
Group type: COMPARATOR
Intervention: GnRHa alone
Number of subjects: 41
Study 10199763 — intervention group
Group type: COMPARATOR
Intervention: GnRHa plus flutamide (250 mg, once daily)
Number of subjects: 41
Study 7766325 — intervention group
Group type: EXPERIMENTAL
Intervention: Early excision and grafting (n = 19)
Number of subjects: 40
Study 7766325 — intervention group
Group type: COMPARATOR
Intervention: Delayed excision and grafting (n = 21)
Number of subjects: 40
Study 2121060 — intervention group
Group type: EXPERIMENTAL
Intervention: Original 'Lifeway' device
Number of subjects: 54
Study 2121060 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified 'Lifeway' device with additional side-holes in GPT
Number of subjects: 54
Study 2121060 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified 'Lifeway' device
Number of subjects: 54
Study 2121060 — intervention group
Group type: COMPARATOR
Intervention: Combination of anaesthesia mask and pharyngeal airway
Number of subjects: 54
Study 530571 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid ester of prednisolone
Number of subjects: 54
Study 530571 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid ester of dexamethasone
Number of subjects: 54
Study 530571 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment (all four corticosteroids)
Number of subjects: 54
Study 29531101 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based behavioral activation with mindfulness (BAM), provided with eight 2-hour weekly sessions.
Number of subjects: 231
Study 29531101 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based behavioral activation with mindfulness (BAM)
Number of subjects: 231
Study 29531101 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 231
Study 25854875 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs treatment (6-week duration)
Number of subjects: 290
Study 24504810 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (standard weight-tiered dose, approximating 10 mg/kg)
Number of subjects: 298
Study 24504810 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (30 mg/kg for 3 months, then standard weight-tiered dose)
Number of subjects: 298
Study 24504810 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 298
Study 24504810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 22433961 — intervention group
Group type: EXPERIMENTAL
Intervention: quadrivalent HPV vaccine
Number of subjects: 600
Study 22433961 — intervention group
Group type: COMPARATOR
Intervention: adjuvant‐containing placebo
Number of subjects: 600
Study 20176772 — intervention group
Group type: EXPERIMENTAL
Intervention: Group programme combining physical activity, education, self-management principles and a 'healthy options' morning tea, once-a-week for seven weeks
Number of subjects: 42
Study 20176772 — intervention group
Group type: COMPARATOR
Intervention: Control group (before crossover)
Number of subjects: 42
Study 18390975 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week high-intensity aerobic exercise programme
Number of subjects: 64
Study 18390975 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone suppression test negative group (control)
Number of subjects: 64
Study 17998631 — intervention group
Group type: EXPERIMENTAL
Intervention: RT+AK-2123
Number of subjects: 333
Study 17998631 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 333
Study 12088330 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative priming
Number of subjects: 0
Study 12088330 — intervention group
Group type: EXPERIMENTAL
Intervention: Different suggestibility measurement procedure
Number of subjects: 0
Study 10363889 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Closure (PC)
Number of subjects: 399
Study 10363889 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene Patch Closure (PTFE)
Number of subjects: 399
Study 10363889 — intervention group
Group type: EXPERIMENTAL
Intervention: Vein Patch Closure (VPC)
Number of subjects: 399
Study 10363889 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 399
Study 10363889 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Patching vs. Primary Closure
Number of subjects: 399
Study 10363889 — intervention group
Group type: COMPARATOR
Intervention: Stenoses of 50%-80%
Number of subjects: 399
Study 10363889 — intervention group
Group type: COMPARATOR
Intervention: Recurrent stenoses >= 80%
Number of subjects: 399
Study 7573816 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE detection in stools of food-sensitization patients
Number of subjects: 434
Study 7573816 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE detection in stools of carriers of intestinal parasites
Number of subjects: 434
Study 7573816 — intervention group
Group type: COMPARATOR
Intervention: IgE detection in stools of healthy subjects
Number of subjects: 434
Study 7573816 — intervention group
Group type: COMPARATOR
Intervention: Alpha-1-antitrypsin determination
Number of subjects: 434
Study 2119901 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 30
Study 2119901 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 30
Study 508508 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of metronidazole (500 mg)
Number of subjects: 0
Study 508508 — intervention group
Group type: COMPARATOR
Intervention: Single intravenous dose of metronidazole (500 mg)
Number of subjects: 0
Study 508508 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of metronidazole (500 mg)
Number of subjects: 0
Study 30801359 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound-guided erector spinae plane block using 20 mL of bupivacaine 0.25% on each side
Number of subjects: 60
Study 30801359 — intervention group
Group type: COMPARATOR
Intervention: Bilateral sham erector spinae plane block using 1 mL of normal saline
Number of subjects: 60
Study 29728074 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline plus 18 mg/mL nicotine e‐cigarette
Number of subjects: 338
Study 29728074 — intervention group
Group type: COMPARATOR
Intervention: Varenicline alone
Number of subjects: 338
Study 27184992 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention questionnaire including questions about QOL goals and concerns
Number of subjects: 64
Study 27184992 — intervention group
Group type: COMPARATOR
Intervention: Control questionnaire asking about symptoms
Number of subjects: 64
Study 24635171 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine amniotic membrane (BAM)
Number of subjects: 49
Study 24635171 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid dressing
Number of subjects: 49